Advisors Capital Management LLC acquired a new position in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 174,496 shares of the medical device company's stock, valued at approximately $4,882,000. Advisors Capital Management LLC owned about 0.34% of AtriCure as of its most recent SEC filing.
Other large investors have also made changes to their positions in the company. Smartleaf Asset Management LLC lifted its stake in shares of AtriCure by 59.8% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company's stock valued at $46,000 after purchasing an additional 429 shares in the last quarter. Scotia Capital Inc. increased its position in AtriCure by 1.2% during the 3rd quarter. Scotia Capital Inc. now owns 37,677 shares of the medical device company's stock worth $1,328,000 after purchasing an additional 457 shares in the last quarter. ProShare Advisors LLC raised its holdings in AtriCure by 6.6% in the fourth quarter. ProShare Advisors LLC now owns 8,819 shares of the medical device company's stock valued at $349,000 after buying an additional 543 shares during the period. Captrust Financial Advisors raised its holdings in AtriCure by 7.9% in the fourth quarter. Captrust Financial Advisors now owns 7,944 shares of the medical device company's stock valued at $314,000 after buying an additional 579 shares during the period. Finally, Mackenzie Financial Corp lifted its position in AtriCure by 5.3% during the fourth quarter. Mackenzie Financial Corp now owns 13,597 shares of the medical device company's stock valued at $545,000 after buying an additional 683 shares in the last quarter. 99.11% of the stock is owned by hedge funds and other institutional investors.
Insider Transactions at AtriCure
In other AtriCure news, insider Vinayak Doraiswamy sold 6,000 shares of the firm's stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $38.88, for a total transaction of $233,280.00. Following the transaction, the insider owned 86,511 shares of the company's stock, valued at approximately $3,363,547.68. This trade represents a 6.49% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Justin J. Noznesky sold 6,182 shares of the business's stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $38.80, for a total transaction of $239,861.60. Following the sale, the insider owned 100,219 shares in the company, valued at $3,888,497.20. This trade represents a 5.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 44,246 shares of company stock worth $1,691,895 over the last ninety days. Insiders own 4.00% of the company's stock.
Wall Street Analysts Forecast Growth
Several equities research analysts have issued reports on ATRC shares. UBS Group decreased their price objective on shares of AtriCure from $55.00 to $50.00 and set a "buy" rating for the company in a research note on Tuesday, July 28th. Citigroup reissued a "market outperform" rating on shares of AtriCure in a research note on Tuesday, July 21st. Canaccord Genuity Group lifted their target price on shares of AtriCure from $53.00 to $55.00 and gave the company a "buy" rating in a report on Wednesday, May 6th. Zacks Research raised shares of AtriCure from a "hold" rating to a "strong-buy" rating in a research report on Friday, July 24th. Finally, Weiss Ratings raised AtriCure from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Wednesday. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $48.50.
Check Out Our Latest Analysis on AtriCure
AtriCure Stock Performance
Shares of ATRC opened at $47.49 on Friday. The stock has a market capitalization of $2.42 billion, a PE ratio of 226.15 and a beta of 1.20. The business's fifty day moving average price is $35.42 and its 200 day moving average price is $31.72. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.22 and a quick ratio of 3.19. AtriCure, Inc. has a 12-month low of $25.36 and a 12-month high of $48.46.
AtriCure (NASDAQ:ATRC - Get Free Report) last announced its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. The business had revenue of $153.60 million during the quarter, compared to the consensus estimate of $151.80 million. During the same quarter in the prior year, the firm earned ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. Equities research analysts forecast that AtriCure, Inc. will post 0.2 EPS for the current year.
About AtriCure
(
Free Report)
AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company's solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.
The company's product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.
See Also
Want to see what other hedge funds are holding ATRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AtriCure, Inc. (NASDAQ:ATRC - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider AtriCure, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AtriCure wasn't on the list.
While AtriCure currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
